Related Experiment Videos
[Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin]
1Department of Infectious Disease, Tokyo Women's Medical University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 18, 2001
Summary
New antibiotics like TAZ/PIPC, Synercid, and Linezolid show promise against resistant Gram-positive infections. Clinical trials indicate varying efficacy for these agents in treating severe bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Rising resistance in Gram-positive cocci leads to more severe infections.
- Emerging antimicrobial agents are crucial for combating these resistant pathogens.
- Key drugs in development include TAZ/PIPC, Synercid, and Linezolid.
Purpose of the Study:
- To review the development and efficacy of new antimicrobial agents against resistant Gram-positive cocci.
- To compare the effectiveness of TAZ/PIPC, Synercid, and Linezolid in clinical settings.
Main Methods:
- Review of randomized clinical trials and clinical trial data.
- Analysis of antimicrobial spectrum and efficacy against resistant organisms like VREF.
- Comparison of TAZ/PIPC with piperacillin (PIPC) for complicated urinary tract infections.
Main Results:
- TAZ/PIPC demonstrated superiority over PIPC for complicated urinary tract infections in Japanese adults.
- Synercid showed 65-70% efficacy in clinical trials for VREF infections.
- Linezolid achieved approximately 75% efficacy in US trials for infections caused by resistant Gram-positive organisms, primarily VREF.
Conclusions:
- TAZ/PIPC, Synercid, and Linezolid represent important advancements in treating infections caused by resistant Gram-positive bacteria.
- These agents offer viable alternatives to vancomycin for specific resistant infections.
- Everninomicin development was halted due to insufficient efficacy and safety data.